Abstract
Current antipsychotic drugs lack material efficacy against the negative symptoms and cognitive deficits of schizophrenia. There is considerable uncertainty regarding the optimal pharmacotherapeutic strategy for treating these and other aspects of psychotic illness. The present review summarises clinical, mutant, and psychopharmacological data related to catechol-O-methyltransferase (COMT), an enzyme involved in the catabolism of catecholamine neurotransmitters, with a view to establishing the antipsychotic potential of compounds targeting the action of this enzyme. The review examines clinical and preclinical genetic data linking COMT gene variation with risk for schizophrenia or specific symptoms or disease endophenotypes. We then summarise data concerning the behavioural effects of COMT inhibitors. These genetic and pharmacological data relating to COMT as a therapeutic target have implications for the development of individualised treatments for treatment-resistant symptoms of schizophrenia, including cognitive dysfunction and, potentially, negative symptoms.
Keywords: Catechol-O-methyltransferase, schizophrenia, antipsychotics, cognition, negative symptoms, Psychotic illness, 22q11-deletion syndrome, Valine, Mrthionine, Cannabis
CNS & Neurological Disorders - Drug Targets
Title:Catechol-O-Methyl Transferase as a Drug Target for Schizophrenia
Volume: 11 Issue: 3
Author(s): Colm M.P. O’Tuathaigh, Lieve Desbonnet, Peter Lee and John L. Waddington
Affiliation:
Keywords: Catechol-O-methyltransferase, schizophrenia, antipsychotics, cognition, negative symptoms, Psychotic illness, 22q11-deletion syndrome, Valine, Mrthionine, Cannabis
Abstract: Current antipsychotic drugs lack material efficacy against the negative symptoms and cognitive deficits of schizophrenia. There is considerable uncertainty regarding the optimal pharmacotherapeutic strategy for treating these and other aspects of psychotic illness. The present review summarises clinical, mutant, and psychopharmacological data related to catechol-O-methyltransferase (COMT), an enzyme involved in the catabolism of catecholamine neurotransmitters, with a view to establishing the antipsychotic potential of compounds targeting the action of this enzyme. The review examines clinical and preclinical genetic data linking COMT gene variation with risk for schizophrenia or specific symptoms or disease endophenotypes. We then summarise data concerning the behavioural effects of COMT inhibitors. These genetic and pharmacological data relating to COMT as a therapeutic target have implications for the development of individualised treatments for treatment-resistant symptoms of schizophrenia, including cognitive dysfunction and, potentially, negative symptoms.
Export Options
About this article
Cite this article as:
M.P. O’Tuathaigh Colm, Desbonnet Lieve, Lee Peter and L. Waddington John, Catechol-O-Methyl Transferase as a Drug Target for Schizophrenia, CNS & Neurological Disorders - Drug Targets 2012; 11 (3) . https://dx.doi.org/10.2174/187152712800672418
DOI https://dx.doi.org/10.2174/187152712800672418 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Are the Antioxidant Properties of Carvedilol Important for the Protection of Cardiac Mitochondria?
Current Vascular Pharmacology The Two Faces of Iminoalditols: Powerful Inhibitors Trigger Glycosidase Activation
Current Enzyme Inhibition Titin and Troponin: Central Players in the Frank-Starling Mechanism of the Heart
Current Cardiology Reviews Potential of Sulphur-containing Amino Acids in the Prevention of Catecholamine-induced Arrhythmias
Current Medicinal Chemistry Treating Sarcopenia in Older and Oldest Old
Current Pharmaceutical Design Endothelial (Dys)Function in Lone Atrial Fibrillation
Current Pharmaceutical Design Role of Oxidative Stress and Mitochondrial Dysfunction in Skeletal Muscle in Type 2 Diabetic Patients
Current Pharmaceutical Design Assessing Myocardial Metabolism with Hybrid PET Imaging: Instrumentation, Concepts, and Workflows
Current Pharmaceutical Design The Emerging Role of Nitrite as an Endogenous Modulator and Therapeutic Agent of Cardiovascular Function
Current Medicinal Chemistry Recent Developments in Cardiovascular Drug Therapy: Treatment of Atrial Arrhythmias with New Class III Drugs and beyond
Current Medicinal Chemistry - Cardiovascular & Hematological Agents A Comparative Literature Review Exploring Hypertension Drugs that Lower Target Organ Damage Above and Beyond Reducing Blood Pressure Based on Research Studies Between 1992 and 2006
Current Hypertension Reviews Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction
Current Topics in Medicinal Chemistry Neurogenesis and Stroke
CNS & Neurological Disorders - Drug Targets Myocardial Quantitative Analysis in Physiological and Pathological Ventricular Hypertrophy: The Increasing Role of Doppler Myocardial Imaging
Current Cardiology Reviews The Impact of Dietary Habits and Nutritional Deficiencies in Urban African Patients Living with Heart Failure in Soweto, South Africa – A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Acute Phase Proteins In Atherosclerosis (Acute Coronary Syndrome)
Cardiovascular & Hematological Agents in Medicinal Chemistry Gender Differences in the Clinical Presentation of Heart Disease
Current Pharmaceutical Design Peripartum Cardiomyopathy: An Intriguing Challenge. Case Report with Literature Review
Current Cardiology Reviews Neuropathological Correlates of Falling in the CC75C Population-Based Sample of the Older Old
Current Alzheimer Research Arrhythmia Pharmacogenomics: Methodological Considerations
Current Pharmaceutical Design